Key Takeaways & Executive Findings
- •• Correction of figure annotation errors in the original article, specifically in Fig. 2C, without affecting the overall results and conclusions. • The original study identified murine skin-derived multipotent papillary dermal fibroblast progenitors with germline potential in vitro. • The correction ensures accurate representation of gene expression trends in the RNA velocity and trajectory analysis. • The authors confirm the integrity of the scientific findings despite the typesetting error.
Abstract
Correction to: Stem Cell Research & Therapy (2023) 14:17. The authors note that during the preparation of the manuscript, the track plot included the expression trends of 14 genes (with Tk1 and Pclaf repeated twice), but only 13 gene symbols were labeled, resulting in a mismatch and repeat of the trackplot with the image on the right. This error occurred during the typesetting process of the original figures. The authors have corrected the annotations in Fig. 2C as shown ahead in this correction article, apologise for the error, and confirm that the overall results and conclusions are not affected by this change.
1. Introduction
This article is a correction notice for the original research paper titled 'Murine skin-derived multipotent papillary dermal fibroblast progenitors show germline potential in vitro' published in Stem Cell Research & Therapy (2023) 14:17. The correction addresses an error that occurred during the typesetting process of the original figures, specifically in Fig. 2C, where the track plot included expression trends of 14 genes but only 13 gene symbols were labeled, leading to a mismatch and repetition.
The authors have corrected the annotations in Fig. 2C and confirm that the overall results and conclusions of the study are not affected by this change. The correction ensures the accuracy and reliability of the published data for the scientific community.
Loading authentic research manuscript (Pages 1–5)...
Wei Ge, Yuan-Chao Sun, Tian Qiao, Hai-Xia Liu, Tao-Ran He, Jun-Jie Wang, Chun-Lei Chen, Shun-Feng Cheng, Paul W. Dyce, Massimo De Felici, Wei Shen (2026). Correction: Murine skin-derived multipotent papillary dermal fibroblast progenitors show germline potential in vitro. Stem Cell Research & Therapy. https://doi.org/10.1186/s13287-024-03838-6
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the purpose of this correction article?
This correction article addresses an error in the original research paper's Fig. 2C, where the track plot had a mismatch in gene labels. The authors corrected the annotations and confirmed that the overall results and conclusions remain unaffected.
What was the original article about?
The original article, published in Stem Cell Research & Therapy (2023) 14:17, reported that murine skin-derived multipotent papillary dermal fibroblast progenitors show germline potential in vitro.
Does the correction affect the scientific conclusions of the study?
No, the authors explicitly state that the overall results and conclusions are not affected by the correction.
What specific error was corrected?
The error was in Fig. 2C, where the track plot included expression trends of 14 genes but only 13 gene symbols were labeled, causing a mismatch and repetition. The annotations were corrected.
How can I access the original article?
The original article can be accessed via the DOI: 10.1186/s13287-023-03243-5.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.